MedCity News June 9, 2024
Frank Vinluan

Geron Corporation’s Rytelo is now FDA approved for treating anemia caused by myelodysplastic syndromes. The new drug will compete against Reblozyl, a blockbuster Bristol Myers Squibb medicine.

The FDA has approved a Geron Corporation treatment for anemia stemming from a particular type of blood cancer, giving the company its first commercialized product and the opportunity to compete against a blockbuster Bristol Myers Squibb drug.

The Geron drug, imetelstat, is approved to treat adults with low- to intermediate-risk myelodysplastic syndromes. The regulatory decision comes three months after an FDA advisory committee voted that the benefits of the drug outweigh its risks. Foster City, California-based Geron will commercialize its new drug under the brand name Rytelo.

Myelodysplastic syndromes (MDS) are a group...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article